SavedAdd your journal

Journals / Turkish Journal of Internal Medicine / 2026 / Volume: 8

Targeting Inflammation in CKD-Related Anemia: The Emerging Role of Lactoferrin as an Adjunctive Therapy

Harsh J Shah(La Renon Healthcare Pvt. Ltd., Ahmedabad, India)0009-0008-6865-1770
Jacky K Pariyani(La Renon Healthcare Pvt. Ltd., Ahmedabad, India)0009-0009-2587-8059
Kalyani V Shinde(La Renon Healthcare Pvt. Ltd., Ahmedabad, India)0009-0003-9905-9589
Dharmil P Pandya(La Renon Healthcare Pvt. Ltd., Ahmedabad, India)0009-0007-0819-8006
Bhakti A Dave(La Renon Healthcare Pvt. Ltd., Ahmedabad, India)0009-0005-4403-0345
Megha M Lokhande(La Renon Healthcare Pvt. Ltd., Ahmedabad, India)0009-0001-9678-2793
Pages
—
Publication Date
2026-08-28
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Its potential effects on the IL-6–hepcidin–ferroportin axis may complement established ESA and iron therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Chronic kidney disease (CKD)-associated anemia is substantially driven by chronic inflammation, which promotes hepcidin upregulation, restricts iron availability, and impairs erythropoiesis.
📊
Key Findings & Data:Methods: This narrative review was based on a literature search of PubMed, Scopus, and Google Scholar for articles published between January 2000 and March 2026, using combinations of the terms “chronic kidney disease,” “anemia,” “inflammation,” “hepcidin,” and “lactoferrin.” Results: Chronic inflammation contributes to CKD-associated anemia through interleukin-6-mediated hepcidin upregulation, ferroportin degradation, impaired iron absorption and mobilization, and cytokinemediated suppression of erythropoiesis.
💡
Conclusion & Impact:Its potential effects on the IL-6–hepcidin–ferroportin axis may complement established ESA and iron therapy.
🔬Design:Review & Systematic Survey
📍Scope:2000 Verileri
⚙️Variables:Chronic Kidney Disease · CKD-associated anemia · Hepcidin Dysregulation

Abstract

Objective: Chronic kidney disease (CKD)-associated anemia is substantially driven by chronic inflammation, which promotes hepcidin upregulation, restricts iron availability, and impairs erythropoiesis. Conventional therapies, including erythropoiesis-stimulating agents and iron supplementation, primarily address erythropoietin deficiency and iron depletion but do not directly target the underlying inflammatory pathways. This narrative review evaluates the role of inflammation in CKD-associated anemia and examines the emerging potential of lactoferrin as an adjunctive therapeutic approach. Methods: This narrative review was based on a literature search of PubMed, Scopus, and Google Scholar for articles published between January 2000 and March 2026, using combinations of the terms “chronic kidney disease,” “anemia,” “inflammation,” “hepcidin,” and “lactoferrin.” Results: Chronic inflammation contributes to CKD-associated anemia through interleukin-6-mediated hepcidin upregulation, ferroportin degradation, impaired iron absorption and mobilization, and cytokinemediated suppression of erythropoiesis. Lactoferrin, an iron-binding glycoprotein with anti-inflammatory, immunomodulatory, and iron-regulatory properties, may counter these mechanisms by reducing inflammatory signaling, modulating hepcidin expression, and improving functional iron availability. Clinical studies have generally reported improvements in hemoglobin, with several studies also reporting favorable changes in hepcidin levels and inflammatory markers, supporting the potential anti-inflammatory and iron-regulatory effects of lactoferrin. Conclusion: Lactoferrin represents a promising adjunctive approach for inflammation-driven CKD-associated anemia, particularly functional iron deficiency. Its potential effects on the IL-6–hepcidin–ferroportin axis may complement established ESA and iron therapy.

🔖

Cite This Article

Shah, H. J., Pariyani, J. K., Shinde, K. V., Pandya, D. P., Dave, B. A., Lokhande, M. M. (2026). Targeting Inflammation in CKD-Related Anemia: The Emerging Role of Lactoferrin as an Adjunctive Therapy. Turkish Journal of Internal Medicine, Volume: 8. https://doi.org/10.46310/tjim.1976160

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (71)

  1. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80(1):17-28. doi:10.1038/ki.2010.483.
  2. Lu Y, Wang L, Ma J, Hu Y, Zheng R, Liu L, et al. The global burden of chronic kidney disease attributable to high sodium intake: a comprehensive analysis of trends from 1990 to 2021 and burden prediction to 2040. Front Nephrol (Lausanne). 2025;5:1630867. doi:10.3389/fneph.2025.1630867.
  3. GBD 2023 Chronic Kidney Disease Collaborators. Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. Lancet. 2025;406(10518):2461-82. doi:10.1016/S0140-6736(25)01853-7.
  4. Plonsky-Toder M, Magen D, Pollack S. Innate immunity and CKD: is there a significant association? Cells. 2023;12(23):2714. doi:10.3390/cells12232714.
  5. Stenvinkel P, Chertow GM, Devarajan P, Levin A, Andreoli SP, Bangalore S, et al. Chronic inflammation in chronic kidney disease progression: role of Nrf2. Kidney Int Rep. 2021;6(7):1775-87. doi:10.1016/j.ekir.2021.04.023.
  6. Rispoli RM, Popolo A, De Fabrizio V, d’Emmanuele di Villa Bianca R, Autore G, Dalli J, et al. Targeting inflammatory imbalance in chronic kidney disease: focus on anti-inflammatory and resolution mediators. Int J Mol Sci. 2025;26(7):3072. doi:10.3390/ijms26073072.
  7. Portoles J, Martin L, Broseta JJ, Cases A. Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents. Front Med (Lausanne). 2021;8:642296. doi:10.3389/fmed.2021.642296.
  8. Badura K, Janc J, Wasik J, Gnitecki S, Skwira S, Młynarska E, et al. Anemia of chronic kidney disease: a narrative review of its pathophysiology, diagnosis, and management. Biomedicines. 2024;12(6):1191. doi:10.3390/biomedicines12061191.
  9. Francis A, Harhay MN, Ong ACM, Tummalapalli SL, Ortiz A, Fogo AB, et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol. 2024;20(7):473-85. doi:10.1038/s41581-024-00820-6.
  10. Suriyong P, Ruengorn C, Shayakul C, Anantachoti P, Kanjanarat P. Prevalence of chronic kidney disease stages 3-5 in low- and middle-income countries in Asia: a systematic review and meta-analysis. PLoS One. 2022;17(2):e0264393. doi:10.1371/journal.pone.0264393.
  11. Shahbazi F, Doosti-Irani A, Soltanian A, Poorolajal J. Global forecasting of chronic kidney disease mortality rates and numbers with the generalized additive model. BMC Nephrol. 2024;25:286. doi:10.1186/s12882-024-03720-w.
  12. Lu P, Yu M, Wei M, Kuo KL. The therapeutic strategies for uremic toxins control in chronic kidney disease. Toxins (Basel). 2021;13(8):573. doi:10.3390/toxins13080573.
  13. Brito RBDO, Rebello JF, Grabulosa CC, Pinto W, Morales A Jr, Elias RM, et al. 25-vitamin D reduces inflammation in uremic environment. Sci Rep. 2020;10:128. doi:10.1038/s41598-019-56874-1.
  14. Jha PK, Nakano T, Itto LYU, Barbeiro MC, Lupieri A, Aikawa E, et al. Vascular inflammation in chronic kidney disease: the role of uremic toxins in macrophage activation. Front Cardiovasc Med. 2025;12:1574489. doi:10.3389/fcvm.2025.1574489.
  15. Kelly DM, Kelleher EM, Rothwell PM. The kidney-immune-brain axis: the role of inflammation in the pathogenesis and treatment of stroke in chronic kidney disease. Stroke. 2025;56(4):1069-81. doi:10.1161/STROKEAHA.124.047070.
  16. Honda T, Hirakawa Y, Nangaku M. The role of oxidative stress and hypoxia in renal disease. Kidney Res Clin Pract. 2019;38(4):414-26. doi:10.23876/j.krcp.19.063.
  17. Haase VH. Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease. Kidney Int Suppl. 2021;11(1):8-25. doi:10.1016/j.kisu.2020.12.002.
  18. Yan Z, Xu G. A novel choice to correct inflammation-induced anemia in CKD: oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat. Front Med (Lausanne). 2020;7:393. doi:10.3389/fmed.2020.00393.
  19. Dhillon S. Desidustat: first approval. Drugs. 2022;82(11):1207-12. doi:10.1007/s40265-022-01744-w.
  20. Tyagi J, Kaur M, Moola S, Ramachandran R, Meena P, Bajpai D, et al. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia in non-dialysis dependent chronic kidney disease: systematic review and meta-analysis of randomized controlled trials. Indian J Nephrol. 2025;35(2):217-33. doi:10.25259/ijn_382_23.
  21. Stoumpos S, Crowe K, Sarafidis P, Barratt J, Bolignano D, Del Vecchio L, et al. Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association. Nephrol Dial Transplant. 2024;39(10):1710-30. doi:10.1093/ndt/gfae075.
  22. Bartnicki P. Hypoxia-inducible factor prolyl hydroxylase inhibitors as a new treatment option for anemia in chronic kidney disease. Biomedicines. 2024;12(8):1884. doi:10.3390/biomedicines12081884.
  23. Li Z, Shen L, Tu Y, Lu S, Liu B. Hypoxia-inducible factor-prolyl hydroxylase inhibitors in treatment of anemia with chronic disease. Chin Med J (Engl). 2025;138(12):1424-32. doi:10.1097/CM9.0000000000003470.
  24. Xie T, Yao L, Li X. Advance in iron metabolism, oxidative stress and cellular dysfunction in experimental and human kidney diseases. Antioxidants (Basel). 2024;13(6):659. doi:10.3390/antiox13060659.
  25. Matsuoka T, Abe M, Kobayashi H. Iron metabolism and inflammatory mediators in patients with renal dysfunction. Int J Mol Sci. 2024;25(7):3745. doi:10.3390/ijms25073745.
  26. Ganz T, Nemeth E. Iron homeostasis in host defence and inflammation. Nat Rev Immunol. 2015;15(8):500-10. doi:10.1038/nri3863.
  27. Li XJ, Shan QY, Wu X, Miao H, Zhao YY. Gut microbiota regulates oxidative stress and inflammation: a double-edged sword in renal fibrosis. Cell Mol Life Sci. 2024;81:480. doi:10.1007/s00018-024-05532-5.
  28. Lau WL, Kalantar-Zadeh K, Vaziri ND. The gut as a source of inflammation in chronic kidney disease. Nephron. 2015;130(2):92-8. doi:10.1159/000381990.
  29. Aboalfarh M, Elshinnawy H, Kamel S, Abdelmegied S, Mansour A, Abdelwahab K. Effect of lactoferrin therapy on interleukin 6, anemia and malnutrition in prevalent hemodialysis patients. Egyptian Journal of Haematology. 2025;50(3):755-9. doi:10.4103/ejh.ejh_52_24.
  30. Kohlová M, Amorim CG, Araújo A, Santos-Silva A, Solich P, Montenegro MCBSM. The biocompatibility and bioactivity of hemodialysis membranes: their impact in end-stage renal disease. J Artif Organs. 2019;22(1):14-28. doi:10.1007/s10047-018-1059-9.
  31. Lonnemann G. Chronic inflammation in hemodialysis: the role of contaminated dialysate. Blood Purif. 2000;18(3):214-23. doi:10.1159/000014420.
  32. Gubernatorova EO, Samsonov MY, Drutskaya MS, Lebedeva S, Bukhanova D, Materenchuk M, et al. Targeting inerleukin-6 for renoprotection. Front Immunol. 2024;15:1502299. doi:10.3389/fimmu.2024.1502299.
  33. Huang B, Lang X, Li X. The role of IL-6/JAK2/STAT3 signaling pathway in cancers. Front Oncol. 2022;12:1023177. doi:10.3389/fonc.2022.1023177.
  34. Anders HJ. Of inflammasomes and alarmins: IL-1β and IL-1α in kidney disease. J Am Soc Nephrol. 2016;27(9):2564-75. doi:10.1681/ASN.2016020177.
  35. Taguchi S, Azushima K, Yamaji T, Urate S, Suzuki T, Kobayashi R, et al. Effects of tumor necrosis factor-α inhibition on kidney fibrosis and inflammation in a mouse model of aristolochic acid nephropathy. Sci Rep. 2021;11:23587. doi:10.1038/s41598-021-02864-1.
  36. Nickerson PW, Bohmig GA, Chadban S, Kumar D, Mannon RB, van Gelder T, et al. Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: phase 3 IMAGINE study rationale and design. Trials. 2022;23(1):1042. doi:10.1186/s13063-022-06897-3.
  37. Zhang H, Sun SC. NF-κB in inflammation and renal diseases. Cell Biosci. 2015;5:63. doi:10.1186/s13578-015-0056-4.
  38. Ren N, Wang WF, Zou L, Zhao YL, Miao H, Zhao YY. The nuclear factor kappa B signaling pathway is a master regulator of renal fibrosis. Front Pharmacol. 2024;14:1335094. doi:10.3389/fphar.2023.1335094.
  39. Luo Y, Long M, Wu X, Zeng L. Targeting the NLRP3 inflammasome in kidney disease: molecular mechanisms, pathogenic roles, and emerging small-molecule therapeutics. Front Immunol. 2025;16:1703560. doi:10.3389/fimmu.2025.1703560.
  40. Zheng Z, Xu K, Li C, Qi C, Fang Y, Zhu N, et al. NLRP3 associated with chronic kidney disease progression after ischemia/reperfusion-induced acute kidney injury. Cell Death Discov. 2021;7(1):324. doi:10.1038/s41420-021-00719-2.
  41. Xiang H, Zhu F, Xu Z, Xiong J. Role of inflammasomes in kidney diseases via both canonical and non-canonical pathways. Front Cell Dev Biol. 2020;8:106. doi:10.3389/fcell.2020.00106.
  42. Gluba-Brzozka A, Franczyk B, Olszewski R, Rysz J. The influence of inflammation on anemia in CKD patients. Int J Mol Sci. 2020;21(3):725. doi:10.3390/ijms21030725.
  43. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO 2026 clinical practice guideline for the management of anemia in chronic kidney disease. Kidney Int. 2026;109(Suppl 1S):S1-99. doi:10.1016/j.kint.2025.06.006.
  44. Sharma N, Gay M, Tawadrous M, Lin T. Therapeutic advancements in anemia of chronic kidney disease and end stage kidney disease. Medical Research Archives. 2024;12(10):1-8. doi:10.18103/mra.v12i10.5815.
  45. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23(10):1631-4. doi:10.1681/ASN.2011111078.
  46. Hashmi MF, Shaikh H, Rout P. Anemia of chronic kidney disease. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539871/.
  47. Coyne DW, Fleming R. Will targeting interleukin-6 in the anemia of CKD change our treatment paradigm? J Am Soc Nephrol. 2021;32(1):6-8. doi:10.1681/ASN.2020101476.
  48. Raj DSC. Role of interleukin-6 in the anemia of chronic disease. Semin Arthritis Rheum. 2009;38(5):382-8. doi:10.1016/j.semarthrit.2008.01.006.
  49. Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019;133(1):40-50. doi:10.1182/blood-2018-06-856500.
  50. Bissinger R, Schaefer L, Bohnert BN, Schork A, Hoerber S, Peter A, et al. GFR is a key determinant of red blood cell survival in anemia associated with progressive CKD. Kidney Int Rep. 2025;10(3):730-42. doi:10.1016/j.ekir.2024.12.023.
  51. Straat M, van Bruggen R, de Korte D, Juffermans NP. Red blood cell clearance in inflammation. Transfus Med Hemother. 2012;39(5):353-60. doi:10.1159/000342229.
  52. Adamson JW. Hyporesponsiveness to erythropoiesis stimulating agents in chronic kidney disease: the many faces of inflammation. Adv Chronic Kidney Dis. 2009;16(2):76-82. doi:10.1053/j.ackd.2008.12.009.
  53. Gutierrez OM. Treatment of iron deficiency anemia in CKD and end-stage kidney disease. Kidney Int Rep. 2021;6(9):2261-9. doi:10.1016/j.ekir.2021.05.020.
  54. Sood V, Kamboj K, Bhatia P, Kaur P, Kumar V, Singh H, et al. A randomized trial of once daily versus twice daily dosing of oral iron in CKD. Sci Rep. 2023;13(1):141. doi:10.1038/s41598-022-26589-x.
  55. Kroot JJC, Kemna EHJM, Bansal SS, Busbridge M, Campostrini N, Girelli D, et al. Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica. 2009;94(12):1748-52. doi:10.3324/haematol.2009.010322.
  56. Diepeveen LE, Laarakkers CMM, Martos G, Pawlak ME, Uğuz FF, Verberne KESA, et al. Provisional standardization of hepcidin assays: creating a traceability chain with a primary reference material, candidate reference method and a commutable secondary reference material. Clin Chem Lab Med. 2019;57(6):864-72. doi:10.1515/cclm-2018-0783.
  57. Macdougall IC, Bircher AJ, Eckardt KU, Obrador GT, Pollock CA, Stenvinkel P, et al. Iron management in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2016;89(1):28-39. doi:10.1016/j.kint.2015.10.002.
  58. Li X, Kshirsagar AV, Brookhart MA. Safety of intravenous iron in hemodialysis patients. Hemodial Int. 2017;21(Suppl 1):S93-103. doi:10.1111/hdi.12558.
  59. Yadav R, Sangha SS, Yadav S, Sharma P, Shah H, Bhowmik D. A clinical study to evaluate the anti-inflammatory effect of lactoferrin + disodium guanosine monophosphate therapy in the patients with chronic kidney disease. J Assoc Physicians India. 2025;73(1):18-22. doi:10.59556/japi.73.0757.
  60. Kekan K, Divyaveer S, Kashyap M, Premkumar M, Zohmangaihi D, Mallik N, et al. Effectiveness of lactoferrin in the treatment of anemia in chronic kidney disease: a single-center pilot study. Indian J Nephrol. 2024;34(3):222-7. doi:10.4103/ijn.ijn_13_23.
  61. Mahmoud RMA, Mohammed A. Lactoferrin: a promising new player in treatment of iron deficiency anemia in patients on regular hemodialysis: a randomized controlled trial. Saudi J Kidney Dis Transpl. 2023;34(3):235-41. doi:10.4103/1319-2442.393996.
  62. Lepanto MS, Rosa L, Cutone A, Conte MP, Paesano R, Valenti P. Efficacy of lactoferrin oral administration in the treatment of anemia and anemia of inflammation in pregnant and non-pregnant women: an interventional study. Front Immunol. 2018;9:2123. doi:10.3389/fimmu.2018.02123.
  63. Hegazy SK, Koura MSED, Elharoun MS. Oral lactoferrin as a treatment of pediatrics’ anemia resulted from chronic kidney diseases: a randomized controlled trial. Sci Rep. 2025;15:4380. doi:10.1038/s41598-025-88506-2.
  64. Arain MA, Khaskheli GB, Barham GS, Marghazani IB. Lactoferrin’s role in modulating NF-κB pathway to alleviate diabetes-associated inflammation: a novel in-silico study. Heliyon. 2024;10(14):e34051. doi:10.1016/j.heliyon.2024.e34051.
  65. Iwamoto Y, Yamakoshi S, Sekimoto A, Hosomi K, Toyama T, Saito Y, et al. Lactoferrin attenuates renal fibrosis and uremic sarcopenia in a mouse model of adenine-induced chronic kidney disease. J Nutr Biochem. 2025;146:110039. doi:10.1016/j.jnutbio.2025.110039.
  66. Kashyap M, Smita D, Kekan K, Premkumar M, Zohmangaihi D, Mallik N, et al. WCN23-0108 effectiveness of lactoferrin in the treatment of anemia in chronic kidney disease: a single center piolt study evidence. Kidney Int Rep. 2023;8(3):S133. doi:10.1016/j.ekir.2023.02.302.
  67. Kekan K, Divyaveer S, Kashyap M, Prajapati K, Premkumar M, Zohmangaihi D, et al. WCN24-1274 the effect of lactoferrin on hemoglobin, erythroferrone and hepcidin levels in chronic kidney disease. Kidney Int Rep. 2024;9(4):S119-20. doi:10.1016/j.ekir.2024.02.246.
  68. Abdelwahab KG, Elshinnawy HA, Elsaid TW, Mohammed MA, Elsharabasy RM. Study of the effect and safety of oral lactoferrin therapy for functional iron deficiency anemia in prevalent hemodialysis patients. Egyptian Journal of Haematology. 2024;49(2):142-6. doi:10.4103/ejh.ejh_79_23.
  69. Divyaveer S, Kekan K, Kashyap M, Prajapati K, Premkumar M, Zohmangaihi D, et al. WCN24-1323 to determine the efficacy of lactoferrin in improving hemoglobin levels in chronic kidney disease patients with iron deficiency anemia. Kidney Int Rep. 2024;9(4):S120. doi:10.1016/j.ekir.2024.02.247.
  70. Peterson RD, Guarneiri LL, Adams CG, Wilcox ML, Clark AJ, Rudemiller NP, et al. A randomized, double-blind, controlled trial to assess the effects of lactoferrin at two doses vs active control on immunological and safety parameters in healthy adults. Int J Toxicol. 2025;44(1):12-28. doi:10.1177/10915818241293723.
  71. Kowalczyk P, Kaczyńska K, Kleczkowska P, Bukowska-Ośko I, Kramkowski K, Sulejczak D. The lactoferrin phenomenon: a miracle molecule. Molecules. 2022;27(9):2941. doi:10.3390/molecules27092941.